Machine perfusion strategies in liver transplantation

Andrea Schlegel¹²³, Xavier Muller¹, Philipp Dutkowski³

Introduction

It has been an ongoing and fascinating dream for more than 100 years to keep organs alive outside of the human body (1). However, only relatively small steps have been made to achieve this prestigious goal, despite numerous technical advances in the field of organ perfusion, including sophisticated pump heads, shielded tubes, filter developments, blood based perfusates, new oxygen carriers or computerized fully automatic circuit controls (2). Of note, while the process of organ donation, cold storage and transport appears completely reversible in healthy livers upon implantation in-vivo, with full function for many years, explanted organs, even of “good quality”, experience severe injury during only a few hours or days of cold storage or ex-situ perfusion (3). The reason behind remains the poorly understood metabolic needs, that determine pathways of injury or repair after cold or warm ischemia (4). Even more challenging is the task, therefore, to improve or repair injured organs ex-situ (Figure 1), a claim, which has however been frequently used by several investigators, in face of an ongoing organ shortage (5-8).

In this review we specifically aim to describe limitations of ex-situ repair of marginal livers by different perfusion techniques. We summarize the current understanding of underlying mechanisms of ex- and in-situ perfusion techniques. Next, we discuss which graft types may benefit most from perfusion techniques, and highlight the current understanding of liver viability testing. Finally, we present results from recent clinical trials involving machine liver perfusion, and analyze the value of different outcome parameters, currently used as endpoints for randomized controlled trials in the field.

What are the main machine liver perfusion concepts?

Two main ex-situ perfusion approaches for livers have...
been recently introduced in the clinic, which differ fundamentally in terms of their logistics, and also in terms of their protective mechanism. First, an upfront machine perfusion, immediately after standard procurement, aims to replace the conventional cold storage (“icebox”) (Figures 1, 2) (6). For this purpose, the organ is placed after procurement on a transportable device, and undergoes continuous perfusion until implantation in the recipient centre (2,6). Sophisticated and expensive systems are used for this approach, mostly at normothermic (NMP) or subnormothermic (SMP) temperatures, with a blood-based perfusate (Organox®, Transmedics®, Liver Assist®) (2,6,9-12). A modification of this technique involves an even earlier start of machine liver perfusion already in the donor, e.g., normothermic regional perfusion (NRP), instead of the routine cold in-situ organ flush (Figure 2) (13,14). Following donor cannulation after cardiac arrest and stand off period, NRP is an immediate in-situ perfusion of abdominal organs.
with donor blood for 2–4 hours, where the decision to procure the liver is based on liver enzyme release and lactate values during NRP. In Spain, donor cannulation prior to treatment withdrawal is accepted by law and national data from Maastricht type III donor liver transplantations have therefore shown a very short donor warm ischemia time compared to data provided by other countries (13,14). A logical extreme would be the combination of NRP and NMP, in order to keep the perfused organ without any intermittent cooling and therefore preventing interruption of normothermic perfusion until implantation. This concept leads to a complete abundance of cold ischemia and has been introduced as “ischemia free organ transplantation” in a few human livers (IFOT) (15). Although such procedure avoids repeated temperature changes during liver preservation, the massive technical complexity appears as clear hurdle for a broad clinical introduction (Figure 2).

Figure 2 Currently available preservation technology for in-situ and ex-situ machine liver perfusion. Multiple new technologies for liver graft treatment and assessment are currently used and tested. Two main concepts include first the replacement of cold storage by perfusion or and end-ischemic approach, where livers are perfused after cold storage. Different temperatures and perfusate compositions are in use and one main interest is the definition of clinically relevant viability criteria, to decide if an injured or suboptimal liver can be utilized for transplantation or not. Importantly, multiple reasons apply for the decline of a certain graft at different categories and timepoints between the first donor allocation, liver procurement and implantation at the recipient centre. Clinical trials and case series, which are designed to assess the impact of machine perfusion technology should report such reasons and also the risk factors for livers of the declined cohort.
by a combination of both, defined as controlled oxygenated rewarming (COR) (19-22). Although, these techniques are logistically easier and cheaper, because a device transport is not necessary, the initial period of cold ischemia induces severe metabolic depletion before perfusion is started, particularly in high-risk grafts, such as steatotic or donation after circulatory death (DCD) livers (Figures 2, 3) (23).

Besides the timing of machine perfusion, the perfusate composition varies substantially among techniques at all temperatures (9,24). While normothermic or subnormothermic perfusions require the presence of red blood cells or artificial oxygen carriers, cold perfusion technologies rely on the amount of dissolved oxygen in the perfusate (9). Hypothermic oxygenated perfusion

Figure 3 Mechanism of reoxygenation of ischemic liver tissue at different temperatures. Ischemic cells, experience a rapid loss of energy, and most adenosine triphosphate (ATP)—dependent processes are therefore on hold. This phenomenon is paralleled by a significant accumulation of NADH, citric acid cycle- and purine-metabolites, mainly succinate, hypoxanthine, and xanthine. Upon normothermic liver reperfusion, accumulated electron donors, such as NADH and succinate, deliver high amounts of electrons to mitochondrial complex I and II, while ADP is not yet available for the ATP synthetase (complex V), due to previous nucleotide breakdown during ischemia (“wheel is blocked”). This results in an intermittent blockage of proton back flow through the inner mitochondrial membrane, with consecutive high proton motive force, and subsequently reverse electron transfer (RET) between complex II and I, leading to the release of reactive oxygen species (ROS)—from complex I, which occurs within the first few minutes after normothermic reoxygenation. Further parameters, including DAMPs and different cytokines, which are used for viability assessment, appear just downstream. To minimize upfront mitochondrial injury during reoxygenation, reintroduction of oxygen at temperatures below the Arhenius breakpoint temperature of 15 °C is required. Subsequently, the reactivity of mitochondrial transfer processes is significantly different and appears comparable to hibernating animals or plants. Mitochondria work more effectively at hypothermic temperatures and upload cellular ATP (Complex V; “wheel works properly”), while consuming cell processes are shut down. Hypothermic oxygenated perfusion (HOPE) after ischemia enables slower but congruent proton pumping through complex I, III and IV and protects therefore, first, from significant mitochondrial ROS-release from complex I, and secondly provides uploaded cellular energy reserves prior to organ rewarming and implantation.
(HOPE) at temperatures between 8–12 degrees is therefore performed with high perfusate oxygen concentrations (>80 kPa) (4,25). Of note, any machine liver perfusion in the cold need strict avoidance of too high perfusion pressures to prevent endothelial shear stress with subsequent endothelial injury (25).

What is the potential mechanism of protection of liver perfusion approaches?

The biochemical advantage of normothermic perfusion is the near physiological condition with the option to analyze and treat livers during ex-situ perfusion (23). The disadvantage, however, relies in the fact, that any reperfusion injury is also occurring during normothermic perfusion, as seen in-vivo, even in the absence of leukocytes or platelets, and also if filters for cytokines or danger associated molecular patterns (DAMPs) are used (23,26). This is based on recent evidence that mitochondrial injury is initiated by exposure of hypoxic tissues to oxygen before activation of non-parenchymal liver cells (Figure 3) (27,28). The basic steps of reperfusion injury are consecutively summarized as follows: ischemic cells, regardless of the organ type, experience a rapid loss of energy, and most adenosine triphosphate (ATP)—dependent processes are subsequently on hold (29,30). This phenomenon is paralleled by a massive accumulation of NADH, citric acid cycle- and purine-metabolites, mainly succinate, hypoxanthine, and xanthine (31-33). Upon normothermic liver reperfusion, accumulated electron donors, such as NADH and succinate, deliver high amounts of electrons to mitochondrial complex I and II, while ADP is not yet available for the ATP synthetase (complex V)—dependent processes are subsequently on hold (29,30). This phenomenon is paralleled by a massive accumulation of NADH, citric acid cycle- and purine-metabolites, mainly succinate, hypoxanthine, and xanthine (31-33). Upon normothermic liver reperfusion, accumulated electron donors, such as NADH and succinate, deliver high amounts of electrons to mitochondrial complex I and II, while ADP is not yet available for the ATP synthetase (complex V), due to previous nucleotide breakdown during ischemia (31,34). This results in an intermittent blockage of proton back flow through the inner mitochondrial membrane, with consecutive high proton motive force, and subsequently reverse electron transfer (RET) between complex II and I, leading to reactive oxygen species (ROS)—release at complex I (32,35,36). Any machine perfusion with an oxygenated perfusate after ischemia will therefore induce reperfusion injury to some extent. Importantly, mitochondrial ROS—release occurs within the first minutes of reintroduction of oxygen to ischemic tissues, and triggers an opening of the mitochondrial membrane pore with further release of mitochondrial DNA together with other DAMPs and multiple cytokines (19,35,37). Accordingly, the release of signaling proteins has been recently confirmed during endischemic normothermic perfusion of many different organs, including kidneys, lungs and also livers (3,26,38-41). In contrast, a newly recognized but decisive option to minimize upfront mitochondrial injury during reoxygenation, is cooling of mitochondria below the Arrhenius breakpoint temperature of 15 °C (42-44), thereby inducing significant changes in the reactivity of mitochondrial transfer processes, as seen in hibernating animals or plants (45,46). Likewise and surprisingly, mitochondria work also more effective at hypothermic temperatures in uploading cellular ATP, when consuming processes are shut down (Figure 3) (3,41,47,48). A similar central role of attenuating mitochondria derived oxidative injury is currently also recognized in other biological fields, such as aging and cancer development (49-51). Hypothermic oxygenated perfusion (HOPE) after ischemia protects therefore, first, from significant mitochondrial ROS-release, and secondly provides uploaded cellular energy reserves prior to organ implantation (3,19,36). Both effects depend, however, on the amount of accumulating metabolites during ischemia, which can in principle also lead to an oxidative injury during HOPE. Of note, the changes in mitochondrial metabolism during HOPE are detectable by perfusate analysis during cold perfusion, which will likewise be available as viability parameters in the future (19,52).

The clinical effect of this hypothermic perfusion approach is demonstrated in recent observational studies in Maastricht III DCD livers (53,54) and by a group from Milan in Maastricht II and III DCD livers, where NRP was combined with endischemic HOPE (55,56). These results have been achieved despite the use of extended DCD liver grafts, and are strikingly different from recent outcomes after end-ischemic normothermic perfusion of human livers (20,23).

Which livers would benefit from machine perfusion?

Despite the current hype for machine perfusion technology, cold storage remains effective for many grafts, with low cost and enormous simplicity (57). The transplant community has therefore to define thresholds for marginality, where perfusion concepts could add a relevant benefit. A huge variability exists however between countries, centres and surgeons how to define marginal, extended or high-risk livers including DCD grafts (58), and guidelines are therefore needed in the future (Table 1) (59). For
example, the type and duration of donor warm ischemia is inconsistent in almost every transplant centre and country, e.g., defining functional donor warm ischemia (fDWIT) by an oxygen saturation in peripheral donor blood below <80% or 70% or by a decrease of systolic blood pressure or mean arterial pressure (MAP) below 50 or 60 mmHg (60-62). Additionally, some studies rely more on the duration of the agonal phase (between withdrawal of treatment and circulatory arrest) or asystolic phase, than on fDWIT (time between asystole/circulatory death and cold flush or start of NRP) (63). Donor age is another classical risk factor with huge variations of recommended thresholds for acceptance of DCD livers, ranging between 50 and 90 years of age (63-66). The majority of clinicians would agree, that an advanced donor age >60 years allocates a DCD graft to the high risk or extended criteria donor (ECD) group. However, recently cohort studies have demonstrated comparable outcomes and suggested, that advanced donor age alone should not exclude utilization of an otherwise good DCD liver (64,65). Further risk factors in combination with donor age are needed to completely characterize the level of risk in a donor liver. To describe the entire picture of marginality or an ECD graft appears therefore rather complex and includes multiple risk factors, their thresholds and combinations with recipient risk (52). In addition to donor age, donor BMI, warm and cold ischemia times, level of macrosteatosis, graft type and viral status were frequently considered to impact on graft quality (18,59). Among clinicians, there is a general clinical consensus not to use a very “risky” livers for a sick recipient, including for example candidates with advanced portal vein thrombosis, listed for retransplantation or with higher MELD scores, which are already admitted or ventilated on intensive care unit (ICU) (62,67-71).

Several risk score models were therefore developed to capture the cumulative risk in donors and recipients, for example by combing cold and warm liver ischemia, donor age, recipient age, recipient MELD, surrogate parameters of hepatic steatosis, and retransplantation (62,67,72-74). Despite well-known shortcomings of a relatively low overall positive predictive value of all score models, such systems help to decide which liver could be accepted for which recipient (62,75). In addition to centre and surgeons experience, the national donation rate per million inhabitants significantly impact on the level of donor risk accepted for transplantation. Countries with lower donation rates are forced to accept higher risk livers. One good example is Switzerland or Italy, where DCD livers with a prolonged fDWIT time (median >30 min) are usually accepted, in context of a high waiting list mortality (76). Interestingly, centres in countries with lower donation rate are usually more interested in underlying mechanisms of preservation technology to finally apply the perfusion approach with the greatest impact on the function of high risk liver grafts (16,19,25,47,55,77).

Another part of the strategy to use risky livers is the selection of a fairly healthy recipient, as for example a transplant candidate with good liver function, but suffering from hepatocellular carcinoma (HCC). These patients have a prolonged waiting time, which depends on the extra point policy of allocation systems (MELD- or UKELD system: United Kingdom model of end stage liver disease) (78). Implantation of injured livers in cancer patients may generate however a higher risk for tumor recurrence due to a more pronounced reperfusion injury (79-82). Although retrospective series showed inconsistent results of tumor recurrence in relatively low risk DCD and DBD transplants (79,83,84), utilization of higher risk DCD livers, may need optimization by machine perfusion, particularly when used for tumor patients to avoid higher HCC recurrence rates in the future.

**How good are recent clinical liver perfusion trials?**

The vast majority of clinical studies are retrospective assessments of new preservation techniques demonstrating mainly feasibility. Relevant conclusions are therefore difficult to obtain. While at least five randomized controlled perfusion trials are currently recruiting participants, only one RCT has been completed in 2018 (6,85). In this study, the authors compared normothermic machine liver preservation against conventional cold storage, and chose peak Aspartate-Aminotransferase (AST) as primary endpoint, which is however only a weak parameter of liver injury after transplantation (6). More clinical convincing would be the impact of machine perfusion on post-transplant complications within a reasonable time-period, e.g., 6 months to 1 year, as for example in the two ongoing multicentric randomized machine perfusion trials on hypothermic liver perfusion (HOPE, D-HOPE). Of note, the lack of transparency in reporting of key risk factors makes a real comparison between different transplant centers and new preservation approaches difficult. For example, the reasons for discard of machine perfused livers are frequently subjective and underreported and lead to major selection bias (6). Additionally, parameters of livers,
declined just prior to ex-situ machine perfusion, assuming their quality appears too inferior to achieve a good outcome with normothermic perfusion, are often not described (21,86). Such practice fails to answer the most relevant clinical question, whether certain preservation techniques can increase the utilization rate and provide more livers, previously declined.

Any future clinical trial should base on a uniform policy how to discard livers for transplantation. Unfortunately, most retrospective clinical studies, which aim to assess the impact of NRP or end ischemic NMP, fail to clearly demonstrate, why livers were declined prior to or during perfusion. It is also necessary to report parameters of injury during liver perfusion, similarly as done in kidney and lungs, to quantify the amount of circulating cytokines and DAMPs (26,39,87). In this context, the group of Chris Watson has demonstrated in a very detailed and transparent way, how they use reperfusion injury to assess livers during endischemic NMP (20). These investigators also reported based on which criteria they accepted or declined high-risk livers. In this context, perfusate lactate showed its inferiority to predict liver function and to prevent PNF (20). Additionally, bile flow alone was also a weak predictor of outcomes and complications. However, bile parameters including bicarbonate and pH at a threshold 7.4, clearly discriminated livers with and without biliary complications in this series from Cambridge (20,23). Other retrospective case studies, where liver grafts were assessed during endischemic NMP, did not describe the reasons for decline transparently enough (86). Good DBD livers, declined for logistical reasons (Figure 4), perform equally well on any normothermic device with or without previous cold storage (6,88). In contrast, for example DCD livers or steatotic grafts, accumulate further invisible injury during prolonged cold storage, and experience the full reperfusion injury cascade, which suddenly becomes visible end enables quantification during endischemic NMP (41,89). Based on this, the detailed presentation of reasons why livers were declined, in any clinical series is of utmost importance (Figures 2,4).

What is currently known in terms of viability assessment during machine liver perfusion?

All perfusion techniques have been investigated regarding liver metabolism and release of liver specific enzymes as markers of hepatocellular injury. For example, during NRP or NMP, markers of liver injury are now routinely analyzed and led to a first suggestion of a combination of parameters, which may serve as viability criteria (Figure 2). Yet, most viability markers currently rely rather on measurement of liver injury than on hepatocellular or biliary function. In a recent paper, Watson et al. demonstrated impressively, and very detailed, that such markers appear very insufficient and do not answer the question, if a certain liver is too high risk for transplantation. For example, Lactate clearance requires very few hepatocytes only and when a liver demonstrates lactate clearance, it does not automatically mean, that this graft will work properly in the recipient and moreover protect from ITBL.

Some authors have therefore suggested to assess also bile fluid, not only in terms of quantity, but also the composition. And a bile pH of >7.4 was recently shown to represent appropriate Bicarbonate secretion into bile by Cholangiocytes and therefore protect from ITBL. The use of different markers implies several critical points, not only the type of marker but also the threshold when to accept or not a graft needs to be defined. Our group has worked on new mitochondrial markers, such as flavoproteins released from mitochondrial complex I during normothermic or hypothermic perfusion. Although metabolic assessment of grafts during machine perfusion appears promising and feasible, validation in clinical trials will be needed before establishing routine perfusate analysis for the difficult decision whether to use or not marginal organs.

The currently used markers include bile bicarbonate, pH and perfusate lactate clearance, assessed after 2–4 hours of normothermic perfusion (12,23,48,86). However, the declaration that “liver viability assessment is only feasible at normothermic temperatures” should be applied with caution (5). Numerous proteins and metabolites are also released during hypothermic and subnormothermic machine liver perfusion (90,91). A few of them are currently explored to predict liver function and outcomes after transplantation (19,91,92). A similar set of proteins has also been recently described in kidney perfusates and metabolic changes after reperfusion in brain tissue is very comparable to livers (92).

How should future clinical trials be designed?

The design of the next clinical trial depends on the clinical question to be answered. Here the most burning and difficult one appears as: “Which perfusion technique enables the highest utilization rate of otherwise discarded livers with the best
available outcomes, regarding complications, graft- and patient survival”. Other important parameters, which require assessment are the reliability of viability markers and how cost effective is a specific preservation approach. While several RCTs are currently recruiting transplant recipients, the next clinically relevant trial should compare most recent concepts. For example, continuous with endischemic NMP compared to endischemic HOPE. However, to find a uniform definition of donor and graft risk with guidelines for clinicians how to utilize higher risk livers best for a certain population of liver recipients is at least equally important.

In the next years, we may therefore expect the field to become even more interesting though possibly more difficult, as new devices, technologies and markers will appear and require further comparisons through clinical trials.

Acknowledgments

None.

Footnote

Conflicts of Interest: The authors have no conflicts of interest to declare.
References

33. Siebels I, Dröse S. Q-site inhibitor induced ROS production of mitochondrial complex II is attenuated by TCA cycle dicarboxylates. Biochim Biophys Acta 2013;1827:1156-64.


© HepatoBiliary Surgery and Nutrition. All rights reserved.